Brain Cancer Clinical Trials in Phoenix

Showing 81-100 of 180 trials

Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma

NCT01774253

The purpose of this research study is to evaluate an investigational drug (Vismodegib) for Pontine Glioma that is growing or has come back (reoccurred). This study will look at the tumors response to the study drug, Vismodegib, and will also look at the safety and tolerability of Vismodegib. Vismodegib has been tested in multiple adult clinical trials and one pediatric trial. Laboratory testing in pontine gliomas suggests that this drug may be effective in treating this disease.

Pontine Glioma

Giselle Sholler9 participantsStarted May 2013

Phoenix, Arizona, United States • Grand Rapids, Michigan, United States

SUSPENDEDPhase 3< 1 mile

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

NCT02546102

ICT-107 consists of dendritic cells, prepared from autologous mononuclear cells that are pulsed with six synthetic peptides that were derived from tumor associated antigens (TAA) present on glioblastoma tumor cells. This is a Phase 3 study to evaluate ICT-107 in patients with newly diagnosed glioblastoma. Subjects will be randomized to receive standard of care chemoradiation (temozolomide (TMZ) with either ICT-107 or a blinded control. Reinfusion with the pulsed dendritic cells should stimulate cytotoxic T cells to specifically target glioblastoma tumour cells.

Glioblastoma Multiforme

Precision Life Sciences Group234 participantsStarted Dec 2024

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Duarte, California, United States +62 more locations

Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma

Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

Brain Cancer Trials in Other Cities

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

Expanded Access Protocol Using 131I-MIBG

Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)

Other Conditions in Phoenix